Related Experiment Video
Updated: Mar 25, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Comparison of in vitro antileukemic activity of obatoclax and ABT-737
Małgorzata Opydo-Chanek1, Lidia Mazur2
1Department of Experimental Hematology, Jagiellonian University, Gronostajowa 9, 30-387, Krakow, Poland. malgorzata.opydo-chanek@uj.edu.pl.
Abstract:
Obatoclax and ABT-737 belong to a new class of anticancer agents known as BH3-mimetics. These agents antagonize the anti-apoptotic members of Bcl-2 family. The Bcl-2 proteins modulate sensitivity of many types of cancer cells to chemotherapy. Therefore, the objective of the present study was to examine and compare the antileukemic activity of obatoclax and ABT-737 applied alone, and in combination with anticancer agent, mafosfamide and daunorubicin. The in vitro cytotoxic effects of the tested agents on human leukemia cells were determined using the spectrophotometric MTT test, Coulter electrical impedance method, flow cytometry annexin V-fluorescein/propidium iodide assay, and light microscopy technique. The combination index analysis was used to quantify the extent of agent interactions. BH3 mimetics significantly decreased the leukemia cell viability and synergistically enhanced the cytotoxic effects induced by mafosfamide and daunorubicin. Obatoclax affected the cell viability to a greater degree than did ABT-737. In addition, various patterns of temporary changes in the cell volume and count, and in the frequency of leukemia cells undergoing apoptosis, were found 24 and 48 h after the tested agent application. ABT-737 combined with anticancer agents induced apoptosis more effectively than obatoclax when given in the same combination regimen. The results of the present study point to the different antileukemic activities of obatoclax and ABT-737, when applied alone, and in combination with anticancer agents. A better understanding of the exact mechanisms of BH3 mimetic action is of key importance for their optional use in cancer therapy.
Insights
Obatoclax and ABT-737, BH3-mimetic anticancer drugs, reduced leukemia cell viability. They enhanced chemotherapy effects, with obatoclax showing greater impact alone, while ABT-737 combinations were more effective at inducing apoptosis.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- BH3-mimetics like obatoclax and ABT-737 target anti-apoptotic Bcl-2 proteins.
- Bcl-2 proteins influence cancer cell sensitivity to chemotherapy.
- Understanding BH3-mimetic action is crucial for optimizing cancer therapy.
Purpose of the Study:
- To compare the antileukemic activity of obatoclax and ABT-737.
- To evaluate their effects alone and in combination with mafosfamide and daunorubicin.
- To investigate their impact on leukemia cell viability and apoptosis.
Main Methods:
- In vitro cytotoxicity assessed using MTT assay, Coulter counter, flow cytometry, and light microscopy.
- Combination index analysis quantified drug interactions.
- Cell viability, volume, count, and apoptosis rates were measured at 24 and 48 hours.
Main Results:
- BH3-mimetics decreased leukemia cell viability and synergistically enhanced cytotoxic effects of mafosfamide and daunorubicin.
- Obatoclax demonstrated greater impact on cell viability than ABT-737 when used alone.
- ABT-737 combinations were more effective in inducing apoptosis than obatoclax combinations.
Conclusions:
- Obatoclax and ABT-737 exhibit distinct antileukemic activities.
- Their efficacy varies when used alone versus in combination with standard anticancer agents.
- Further research into BH3 mimetic mechanisms is essential for clinical application.
